&w=3840&q=100)
UBS to pay $300 million in US settlement over Credit Suisse mortgages
The Zurich-based bank said the decision will resolve all of the outstanding payments owed from a settlement on the matter originally made by Credit Suisse in 2017, according to a statement on Monday.
In May, UBS agreed to pay $511 million to settle a separate US investigation into how Credit Suisse Group helped rich Americans evade taxes. Monday's announcement ticks off another matter, with the cost to settle further legacy cases including the fallout from the collapse of Archegos Capital Management in 2021 estimated by Bloomberg Intelligence at around $500 million.
A number of lenders had faced claims over the sale of mortgage securities that plummeted in value during the 2008 financial crisis. The banks faced allegations that they misrepresented the quality of the home loans underpinning these securities in order to win buyers, exacerbating the impact of the sub-prime mortgage collapse.
In 2023, UBS agreed to pay $1.44 billion to settle its own long-running case over US mortgage-backed securities, which was one of the bank's biggest legal headaches at the time.
UBS said it expects Monday's announcement to have a positive impact on its third quarter results as it plans to recognize a credit in the bank's non-core unit as a result of the release of the contingent liability.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
US slams use of AI to personalise airline ticket prices, would investigate
US Transportation Secretary Sean Duffy said Tuesday the department has concerns about the use of AI to set personalised airline ticket prices and will investigate if anyone does so. Last week, Delta Air Lines told lawmakers it will not and has not used AI to set prices for individual consumers. "To try to individualise pricing on seats based on how much you make or don't make or who you are, I can guarantee you that we will investigate if anyone does that," Duffy said. "We would engage very strongly if any company tries to use AI to individually price their seating." Duffy noted Delta clarified that it would not use AI for pricing individual tickets, "and I'll take them at face value." Late last month, Democratic Senators Ruben Gallego, Mark Warner and Richard Blumenthal said they believed the Atlanta-based airline would use AI to set individual prices, which would "likely mean fare price increases up to each individual consumer's personal 'pain point.'" Delta previously said it plans to deploy AI-based revenue management technology across 20 per cent of its domestic network by the end of 2025 in partnership with Fetcherr, an AI pricing company. Fetcherr on its website says its technology is "trusted by the world's leading airlines," and lists Delta, Westjet, Virgin Atlantic, Viva and Azul. American Airlines CEO Robert Isom said last month using AI to set ticket prices could hurt consumer trust. Democratic lawmakers Greg Casar and Rashida Tlaib have introduced legislation to bar companies from using AI to set prices or wages based on Americans' personal data and would specifically ban airlines raising individual prices after seeing a search for a family obituary. Delta said airlines have used dynamic pricing for more than three decades, in which pricing fluctuates based on a variety of factors like overall customer demand, fuel prices and competition, but not a specific consumer's personal information.
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
Time of India
2 minutes ago
- Time of India
BlueStone cuts IPO size to Rs 820 crore, to launch issue on August 11
Academy Empower your mind, elevate your skills Omnichannel jewellery retailer BlueStone Jewellery & Lifestyle has reduced the size of its initial public offering (IPO) as per a revised red herring prospectus filed by the company. The Bengaluru-based company is now looking to raise Rs 820 crore in primary capital against Rs 1,000 crore that it had originally to sources, the company is likely to go public at a valuation of around Rs 7,800 crore, which is less than its last private funding in August 2024, when it raised at a valuation of Rs 8,100 offer-for-sale (OFS) component has also been shrunk to 13.9 million shares, compared to 24 million shares earlier – with investors including venture capital firms Accel , Kalaari Capital, Iron Pillar Fund and Hero group's Sunil Kant Munjal planning to sell fewer shares than before. IvyCap Ventures, which was initially planning to sell 3.1 million shares, is not participating in the OFS which received the Securities and Exchange Board of India's approval in April, will launch its IPO on August 11, as per the reported in June that private wealth management firms 360 One and Centrum Wealth facilitated secondary deals amounting to Rs 300–350 crore in BlueStone. Axis Capital , IIFL Capital and Kotak Mahindra are bankers to BlueStone's reported a 40% increase in operating revenue for fiscal 2025 to Rs 1,770 crore. Its net loss, however, expanded to Rs 222 crore in FY25 from Rs 142 crore in the last few years, investors have turned bullish on the jewellery business. This trend picked up steam after the Tata Group's full acquisition of CaratLane at a valuation of Rs 17,000 crore. The conglomerate had first invested in the startup in 2016, when it was valued at Rs 563 jewellery startup Giva, which specialises in silver products, is also in talks to pick up Rs 450 crore ($53 million) in a financing round led by Creaegis in addition to participation by Premji Invest, Epiq Capital and others.
